TC
CLDX icon

TFS Capital’s Celldex Therapeutics CLDX Stock Holding History

TFS Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-702
Closed -$37K – 685
2016
Q4 		$37K Buy
+702
New +$39.9K 0.01% 699
2016
Q2 		– Sell
-789
Closed -$45K – 991
2016
Q1 		$45K Buy
+789
New +$88.8K 0.01% 955
2015
Q4 		– Sell
-1,651
Closed -$261K – 766
2015
Q3 		$261K Buy
+1,651
New +$467K 0.03% 686

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TFS Capital's CLDX Position: Q1 2017 in Review

TFS Capital sold out of Celldex Therapeutics (CLDX) in Q1 2017, closing a stake of 702 shares — an estimated $37K sold.

TFS Capital first reported a position in CLDX in Q3 2015 and held it in 3 quarters. The position peaked at $261K in Q3 2015. 134 funds tracked by Wall St. Rank hold CLDX as of Q1 2017.

  • TFS Capital reported no remaining Celldex Therapeutics position as of Q1 2017 after selling out during the quarter.
  • TFS Capital sold 702 Celldex Therapeutics shares in Q1 2017, an estimated $37K.
  • TFS Capital first reported a position in Celldex Therapeutics in Q3 2015 and held it in 3 quarters.
  • TFS Capital's Celldex Therapeutics position peaked at $261K in Q3 2015.
  • 134 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.